Effect of Cariprazine on Outcomes in Older-aged and Younger-aged Patients with Bipolar I Disorder: A Post-hoc Analysis: A Post-hoc Analysis
Uloženo v:
| Název: | Effect of Cariprazine on Outcomes in Older-aged and Younger-aged Patients with Bipolar I Disorder: A Post-hoc Analysis: A Post-hoc Analysis |
|---|---|
| Autoři: | Garel, Nicolas, Dols, Annemieke, Yu, Jun, Cresce, Christine Di, Rej, Soham, Sajatovic, Martha |
| Přispěvatelé: | Acuut & Intensieve Zorg Med., Brain |
| Zdroj: | The American Journal of Geriatric Psychiatry. 33:372-386 |
| Informace o vydavateli: | Elsevier BV, 2025. |
| Rok vydání: | 2025 |
| Témata: | Male, Adult, Psychiatric Status Rating Scales, bipolar depression, older age bipolar disorder, Bipolar Disorder, Age Factors, bipolar mania, Cariprazine, Middle Aged, Piperazines, Psychiatry and Mental health, Young Adult, Treatment Outcome, Humans, Female, Geriatrics and Gerontology, Aged, Antipsychotic Agents |
| Popis: | To evaluate cariprazine in adults with older- and younger-age bipolar I disorder (OABD-I and YABD-I) and compare treatment effects between them.Pooled post-hoc analysis of studies in depressive or acute manic/mixed episodes associated with bipolar I disorder.475/1383 patients (34.3%) in 3 depression trials and 238/1037 patients (23.0%) in 3 manic/mixed trials were OABD-I.Depression: placebo, cariprazine 1.5 mg/day, 3.0 mg/day, pooled 1.5-3.0 mg/day. Manic/mixed: placebo, cariprazine 3.0-6.0 mg/day, and 9.0-12.0 mg/day.Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression of Severity (CGI-S), and Young Mania Rating Scale (YMRS).In bipolar I depression, mean change from baseline in MADRS was significantly greater for the pooled cariprazine group vs. placebo in OABD-I (-13.72 vs. -11.98; p < 0.05) and for each cariprazine group vs. placebo among YABD-I. There was no significant difference in treatment effect between OABD-I and YABD-I for either individual cariprazine group vs. placebo. For mania/mixed states, mean change in YMRS was significantly greater for cariprazine 3.0-6.0 mg/day vs. placebo in OABD-I (-19.04 vs. -12.45; p < 0.001) and for both cariprazine groups in YABD-I (-12.49, -19.66 and -18.05 for placebo, cariprazine 3.0-6.0 mg/day and 9.0-12.0 mg/day, respectively [both p < 0.0001 vs. placebo]). There was no significant difference in treatment effect between OABD-I and YABD-I for cariprazine 3.0-6.0 mg/day vs. placebo; there was a significantly higher treatment effect for cariprazine 9.0-12.0 mg/day vs. placebo in the YABD-I subpopulation vs. OABD-I (4.20; p < 0.05).Cariprazine appears to be effective for both depressive and manic/mixed episodes of bipolar I disorder, regardless of age. |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1064-7481 |
| DOI: | 10.1016/j.jagp.2024.12.006 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39855966 https://dspace.library.uu.nl/handle/1874/460480 |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....8a827ec509af404d8829af938090db0b |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | To evaluate cariprazine in adults with older- and younger-age bipolar I disorder (OABD-I and YABD-I) and compare treatment effects between them.Pooled post-hoc analysis of studies in depressive or acute manic/mixed episodes associated with bipolar I disorder.475/1383 patients (34.3%) in 3 depression trials and 238/1037 patients (23.0%) in 3 manic/mixed trials were OABD-I.Depression: placebo, cariprazine 1.5 mg/day, 3.0 mg/day, pooled 1.5-3.0 mg/day. Manic/mixed: placebo, cariprazine 3.0-6.0 mg/day, and 9.0-12.0 mg/day.Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression of Severity (CGI-S), and Young Mania Rating Scale (YMRS).In bipolar I depression, mean change from baseline in MADRS was significantly greater for the pooled cariprazine group vs. placebo in OABD-I (-13.72 vs. -11.98; p < 0.05) and for each cariprazine group vs. placebo among YABD-I. There was no significant difference in treatment effect between OABD-I and YABD-I for either individual cariprazine group vs. placebo. For mania/mixed states, mean change in YMRS was significantly greater for cariprazine 3.0-6.0 mg/day vs. placebo in OABD-I (-19.04 vs. -12.45; p < 0.001) and for both cariprazine groups in YABD-I (-12.49, -19.66 and -18.05 for placebo, cariprazine 3.0-6.0 mg/day and 9.0-12.0 mg/day, respectively [both p < 0.0001 vs. placebo]). There was no significant difference in treatment effect between OABD-I and YABD-I for cariprazine 3.0-6.0 mg/day vs. placebo; there was a significantly higher treatment effect for cariprazine 9.0-12.0 mg/day vs. placebo in the YABD-I subpopulation vs. OABD-I (4.20; p < 0.05).Cariprazine appears to be effective for both depressive and manic/mixed episodes of bipolar I disorder, regardless of age. |
|---|---|
| ISSN: | 10647481 |
| DOI: | 10.1016/j.jagp.2024.12.006 |